CellCentric Secures $220 Million Series D Financing to Advance First-in-Class Oral p300/CBP Inhibitor Inobrodib for Multiple Myeloma

On May 6, in Cambridge and Boston, UK, CellCentric, a clinical-stage biotechnology company developing inobrodib as a first-in-class oral p300/CBP inhibitor for the treatment of multiple myeloma, announced the completion of a $220 million oversubscribed Series D financing. The financing was led by Venrock Healthcare Capital Partners.Fidelity, Sofinova Partners, and HBM Healthcare, along with existing investors RA Capital Management, Forbion, Pfizer, Avego BioScience Capital, and the American Cancer Society's BrightEdge participated. May 2025,CellCentric Announces Completion of $120 Million Series C FinancingRA Capital Management and new investor Forbion co-led the investment.$120 Million Series C Financing to Develop Oral Small Molecule p300/CBP Inhibitors) 2024,CellCentric ObtainedRA Capital's initial investment of $35 million and Pfizer's strategic investment of $25 million.The company was spun out from the University of Cambridge by Azim Surani, a pioneering developmental biologist at Cambridge, who aims to further explore the potential of chromatin-related cell fate control mechanisms to provide new therapeutic approaches.

The proceeds will support the progress of inobrodib through key clinical development studies, including continued participation in the company's recently launched Phase 2 DOMMINO-1 study in the UK and the US, and the initiation of the global Phase 3 DOMMINO-2 trial in the second half of 2026. The funds raised will also be used to expand inobrodib into other combination and maintenance therapy settings.

CellCentric CEO Dr. Will West stated:"We are delighted to have the support of top-tier investors who believe in the potential of inobrodib to address a key need in multiple myeloma, particularly following bispecific T-cell engagers or anti-BCMA therapies. This is an important and growing unmet need. Inobrodib offers a novel oral administration and represents a potential new option for patients. Combined with pomalidomide and dexamethasone as InoPd, we have demonstrated deep responses in heavily pretreated patients with relapsed or refractory multiple myeloma. With this funding, we are well-positioned to complete the registration study for the all-oral triplet therapy and advance our progress in delivering transformative treatments."

The Phase 2 dose optimization data shared at ASH in December 2025 indicate that, compared with historical alternative therapies for heavily pretreated patients with relapsed or refractory multiple myeloma (RRMM), 20mgInobrodibThe response rate of the combination of standard-dose pomalidomide and dexamethasone (InoPd) increased at least twofold (median of five prior treatment lines).

West stated that, with sufficient cash to last until 2029, an initial public offering (IPO) could be possible next year. However, the company is also engaged in parallel discussions regarding mergers and acquisitions.

Ken Greenberg, M.D., Partner at Venrock, stated:"What stands out about inobrodib is the consistency of clinical effectiveness and manageable safety in heavily pretreated populations. An oral medication with a novel additive method can play a significant role in later-line treatment and across the entire field of multiple myeloma therapy. We are excited to support its advancement into pivotal studies."